Daily14d
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA approval for HER2-ultralow metastatic breast cancer
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan ... which were presented at the 2024 American Society of Clinical Oncology (ASCO) Meeting and published in The New England Journal of ...
FiercePharma14d
AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their ... In addition to becoming the first treatment for those whose tumors show a lower level of the HER2 protein ...
Nasdaq14d
FDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast Cancer
(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...
Pharm Exec15d
FDA Approves AstraZeneca, Daiichi Sankyo’s Enhertu for Unresectable or Metastatic Hormone Receptor-Positive, HER2-Low Breast Cancer
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy for adult patients with unresectable or metastatic hormone receptor ...
Contract Pharma15d
AstraZeneca & Daiichi Sankyo’s Enhertu Approved by FDA for Treatment of Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2 ...
Morningstar16d
Daiichi Sankyo Co Ltd
Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
Nasdaq18d
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
The FDA granted approval to AstraZeneca/Daiichi's Dato-DXd for previously ... option fees and milestone payments. The NYSE ARCA Pharmaceutical Index declined 1.6% in the past five trading sessions.
ascopubs.org21d
Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions
Cell-based therapies have become integral to the routine clinical management of hematologic malignancies. Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in immunogenic solid ...
ascopubs.org22d
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...
STAT22d
A next-generation form of chemotherapy wins FDA approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Another day, another president. Good morning! Today, we hear from ...
BioSpace22d
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
The treatment will hit U.S. shelves in approximately two weeks, according to Daiichi Sankyo’s announcement of the approval ... an efficacy estimate that the pharma partners at the time labeled as ...